Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $120

SVB Leerink analyst Rick Bienkowski maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $126 to $120.
byBenzinga Newsdesk
February 16, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

SVB Leerink analyst Rick Bienkowski maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $126 to $120.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0